IP Library › Granted Patent US 10,420,738
Granted Patent B2
US 10,420,738 · App. 14/969,598 · Granted Sep 24, 2019

Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction

Inventors: Norbert Odolczyk (Warsaw, PL); Piotr Zielenkiewicz (Warsaw, PL); Grzegorz Wieczorek (Warsaw, PL); Aleksander Edelman (Chatenay-Malabry, FR); Danielle Tondelier (Le Mesnil-le-Roi, FR); Janine Fritsch (Saint Michel sur Orge, FR)
Assignee: INSTYTUT BIOCHEMII I BIOFIZYKI PAN
A61K31/194A61K31/496A61K31/52A61K31/663C07C233/65C07C235/84C07D219/10C07D401/12C07D473/22C07D473/30C07F9/304C07F9/305C07C2603/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,420,738
App. No.
14/969,598
Granted
Sep 24, 2019
Kind
B2
Abstract

An exemplary embodiment relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. The invention provides compositions, pharmaceutical preparations and methods of correcting the cellular alteration of a mutant CFTR protein wherein the CFTR mutation is a mutation ΔF508-CFTR, or another mutation of class II.

Claims (5)

1. A pharmaceutical composition comprising a compound represented by the following structure:

used for manufacture of a medication for treatment of diseases associated with CFTR protein malfunction,

or its tautomers, E and Z geometric isomers, enantiomers, diastereomers, or pharmaceutically acceptable salts thereof or complexes thereof.

2. The pharmaceutical composition of claim 1 , wherein the compound has an effect on mutant CFTR protein, wherein said CFTR mutation is a mutation ΔF508-CFTR, or another mutation of class II and wherein a mutation ΔF508-CFTR, or another mutation of class II, are involved in CFTR protein malfunction.

3. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition consists essentially of the compound of formula

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2015
From: ODOLCZYK, NORBERT; WIECZOREK, GRZEGORZ; EDELMAN, ALEKSANDER; TONDELIER, DANIELLE; FRITSCH, JANINE; ZIELENKIEWICZ, PIOTR
To: INSTYTUT BIOCHEMII I BIOFIZYKI PAN
Reel/Frame 037298/0476 →
Continuity (3)
Continuation 14829234 · Aug 18, 2015
Continuation In Part 13822584
Related Publication 20160101107A1 · Apr 14, 2016